In Re: Opana ER Antitrust Litigation

  1. February 26, 2016

    Walgreen Booted From Opana MDL But Promises Comeback

    An Illinois federal judge has kicked Walgreen Co. and Rite Aid Corp. out of a mass of consolidated lawsuits accusing Endo and Impax of colluding to prevent a generic version of painkiller Opana ER from coming to market, but an attorney for Walgreen said Friday that the company plans on taking another shot at the suit.

  2. February 11, 2016

    Endo Can't Dump $112M Painkiller Pay-For-Delay Suit

    An Illinois federal judge largely allowed multidistrict litigation to move forward accusing Endo International PLC of engaging in an alleged scheme to pay Impax Laboratories Inc. more than $112 million to delay a generic version of opioid pain medication Opana ER, trimming only a handful of state law claims. 

  3. October 15, 2015

    Endo Lobbies For Dismissal Of Painkiller Pay-For-Delay Suit

    The end payors, direct purchasers and retailers alleging Endo paid roughly $112 million to delay a generic of painkiller Opana ER had ignored parts of a recent decision in a similar antitrust multidistrict litigation they cited in fighting dismissal bids, the drugmaker argued Thursday.

  4. August 24, 2015

    Walgreen, Rite Aid Slam Dismissal Bid in Opana Antitrust MDL

    Attempts by Endo Pharmaceuticals Inc. and Impax Laboratories to dismiss proposed class actions claiming Endo paid about $112 million to delay a generic version of painkiller Opana ER ignore several post-Actavis decisions rejecting similar attempts to dismiss complaints alleging unlawful reverse-payment agreements, two plaintiffs in the case argued Friday.

  5. July 06, 2015

    Endo, Impax Look To Nix Opana Pay-For-Delay Suits

    Endo Pharmaceuticals Inc. and Impax Laboratories sought Friday to dismiss proposed class actions claiming Endo paid more that $112 million to delay a generic version of painkiller Opana ER, saying the plaintiffs hadn't stated a claim under the U.S. Supreme Court's Actavis ruling.